Arrowhead Announces Proposed Underwritten Offering of Common Stock

  Arrowhead Announces Proposed Underwritten Offering of Common Stock

Business Wire

PASADENA, Calif. -- February 18, 2014

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company
developing targeted RNAi therapeutics, today announced its intention to offer
and sell shares of its common stock in an underwritten offering pursuant to
its existing shelf registration statement. All of the shares in the proposed
offering are to be sold by Arrowhead.

Jefferies LLC, Barclays Capital Inc. and Deutsche Bank Securities Inc. are
acting as joint book-runners for the offering. Arrowhead intends to grant the
underwriters a 30-day option to purchase additional shares of its common
stock. The offering is subject to market conditions, and there can be no
assurance as to whether or when the offering may be completed, or the actual
size or terms of the offering.

The securities described above are being offered pursuant to a shelf
registration statement (File No. 333-193748), which was declared effective by
the United States Securities and Exchange Commission (“SEC”) on February 12,
2014.

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy these securities, nor shall there be any sale of these
securities in any jurisdiction in which such offer, solicitation or sale would
be unlawful prior to the registration or qualification under the securities
laws of any such jurisdiction. The offering can be made only by means of a
prospectus supplement and accompanying prospectus, copies of which may be
obtained at the SEC's website at www.sec.gov, or by request at Jefferies LLC,
520 Madison Avenue, 12th Floor, New York, NY 10022, Attention: Prospectus
Department, or by email to Prospectus_Department@Jefferies.com; or Barclays
Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY, 11717, Telephone: (888) 603-5847, email:
barclaysprospectus@broadridge.com; or Deutsche Bank Securities Inc.,
Attention: Prospectus Group, 60 Wall Street, New York, NY 10005-2836 or by
telephone at: (800) 503-4611, or by email at: prospectus.CPDG@db.com.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a biopharmaceutical company developing
targeted RNAi therapeutics. The company is leveraging its proprietary drug
delivery technologies to develop targeted drugs based on the RNA interference
mechanism that efficiently silence disease-causing genes. Arrowhead
technologies also enable partners to create peptide-drug conjugates that
specifically home to cell types of interest while sparing off-target tissues.
Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus
and obesity and partner-based programs in oncology.

Contact:

Arrowhead Research Corporation
Vince Anzalone, CFA
626-304-3400
ir@arrowres.com
 
Press spacebar to pause and continue. Press esc to stop.